Tenax Therapeutics
NASDAQ: TENXChapel Hill, US · Delaware corporation · 1 known investors
Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
Founders & leadership
SR
Stuart RichChief Medical Officer
LR
Lawrence R. HoffmaninInterim Chief Financial Officer
MB
Michael B. JebsenExecutive
CG
Chris GiordanoinPresident and Chief Executive Officer
DR
Doug RandallinChief Business Officer
TS
Tom StaabinChief Financial Officer
TH
Tim HealeyinChief Commercial Officer
DH
Douglas HayinEVP of Regulatory Affairs
SK
So-Young KiminExecutive Vice President of Clinical Development and Strategy
GP
Gregory PepinNamed on SEC filing
JM
James MitchumNamed on SEC filing
AD
Anthony DiTonnoNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$123.2M disclosed across 5 rounds · 2020–2024
▶$99.7MraisedAug 2024 · 24 investors · PharmaceuticalsRule 506(b)
▶$99.7MraisedAug 2024 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael DavidsonDirector
- Stuart RichExecutive Officer, Director
- Lawrence R. HoffmanExecutive Officer
- Christopher T. GiordanoExecutive Officer, Director
- Declan DooganDirector
- June AlmenoffDirector
- Robyn M. HunterDirector
- Gerald T. ProehlDirector
- Offering amount
- $175M
- Amount sold
- $99.7M
- Sales commissions
- $6.8M
- Placement agents
- Leerink Partners LLC, Guggenheim Securities, LLC, Roth Capital Partners, LLC, William Blair & Company, L.L.C.
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedJun 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$8MraisedJun 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith MaherDirector
- Robyn HunterDirector
- Michael DavidsonDirector
- Christopher T. GiordanoExecutive Officer, Director
- Steven BoydDirector
- Declan DooganDirector
- Eliot LurierExecutive Officer
- Gerald ProehlDirector
- June AlmenoffDirector
- Stuart RichExecutive Officer, Director
- Offering amount
- $8M
- Amount sold
- $8M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$10MraisedJul 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael JebsenExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $750K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$5.2MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael B. JebsenExecutive Officer
- James MitchumDirector
- Chris A. RallisDirector
- Ronald R. BlanckDirector
- Gerald ProehlDirector
- Gregory PepinDirector
- Anthony DiTonnoDirector, Executive Officer
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- Sales commissions
- $1.4M
- Placement agents
- H.C. Wainwright & Co., LLC, Ladenburg Thalmann & Co. Inc.
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$317.2KraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$317.2KraisedMar 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael B. JebsenExecutive Officer
- Ronald R. BlanckDirector
- Gregory PepinDirector
- James MitchumDirector
- Chris A. RallisDirector
- Gerald ProehlDirector
- Anthony DiTonnoDirector, Executive Officer
- Offering amount
- $317.2K
- Amount sold
- $317.2K
- Sales commissions
- $206K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Seeking Alpha18 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Tonix Pharmaceuticals Holding16 shared keywordsTonix is a biotechnology company developing therapies for chronic and complex conditions across central nervous system disorders, infectious diseases, immunology/immuno-oncology, and rare diseases. Its pipeline includes candidates for acute stress disorder, PTSD, smallpox/mpox vaccination, organ transplant rejection, and Prader-Willi syndrome.
StockTwits16 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Tenax Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tenax Therapeutics do?
- Tenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
- Who are Tenax Therapeutics's investors?
- Tenax Therapeutics's investors include Vivo Capital.
- How much funding has Tenax Therapeutics raised?
- Tenax Therapeutics has disclosed $123.2M raised across 5 rounds.
- Where is Tenax Therapeutics headquartered?
- Tenax Therapeutics is headquartered in Chapel Hill, US.